Outlook Therapeutics Inc (OTLK)

[exwannabe]

UK and NICE. In the UK the NICE guidance establishes how the NHS will pay for and use drugs.

Read through the most recent guidance for wet AMD. In short, it does not pay for bavi because it is not approved for the indication. It also says generic Lucentis should be used as first choice (because it is cheaper than branded).

What does this mean for Lytevana when they go to NICE to update the guidance?

First, there is no price pressure form the off label bavi. That is very good.

Second, I would guess that they would basically try to split the non branded market with generic Lucentis,

IMO, this is good. My concern with markets like the UK has been they will force the price down close to the off label bavi. And that does not look to be the case.

Have no clue about all the other dozens of EU states,.